Researchers at Baylor College of Medicine have identified a potential new strategy for fighting back against Alzheimer's and Parkinson's diseases, and it targets a stage of disease that current therapeutics do not reach: the moment before toxic protein aggregates form at all.
The study, published in Nature Communications and reported by ScienceDaily on June 21, 2026, found that tubulin — the fundamental building block of microtubules, the internal "railway tracks" that neurons use to transport nutrients, signals, and waste — can prevent both Tau and alpha-synuclein from forming the toxic aggregates that drive neurodegeneration in Alzheimer's and Parkinson's disease, respectively.
The research was led by Dr. Allan Chris M. Ferreon, an associate professor at Baylor, with first author Dr. Lathan Lucas, a postdoctoral associate of biochemistry and molecular pharmacology, and co-first author Phoebe S. Tsoi and co-corresponding author Josephine C. Ferreon. The study was funded by grants from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of General Medical Sciences (NIGMS).
What Tubulin Does — and What Happens When It Fails
In healthy neurons, Tau and alpha-synuclein perform important physiological functions. Tau helps stabilize and maintain microtubules. Alpha-synuclein is involved in the regulation of synaptic signaling. Both proteins exist in a dynamic equilibrium between functional and non-functional states, and both are essential to neuron health when properly regulated.
In Alzheimer's disease, Tau misfolds and aggregates into neurofibrillary tangles. In Parkinson's disease, alpha-synuclein aggregates into Lewy bodies. These aggregates are directly toxic to neurons, disrupting transport networks, triggering inflammation, and ultimately killing cells. Current therapies for both diseases work primarily to remove or reduce aggregates after they have already formed, an intervention that researchers have increasingly recognized as arriving too late.
According to Baylor College of Medicine's official release, the key finding is that tubulin transforms both Tau and alpha-synuclein condensates — microscopic droplets that form inside cells as a precursor step to aggregation — from a pathological state into a physiological one. In the presence of sufficient tubulin, Tau and alpha-synuclein are redirected toward their healthy functional roles rather than clumping into toxic forms.
"Tau and alpha-synuclein are well known for their roles in neurodegenerative diseases like Alzheimer's and Parkinson's. In these conditions, these proteins can misfold, stick together and form harmful aggregates that damage neurons and contribute to memory loss, movement problems and other symptoms," said Dr. Lathan Lucas. "But Tau and alpha-synuclein also have essential physiological roles in healthy neurons — helping to build and stabilize the cell's railway system."
The mechanism tubulin uses is essentially to give both proteins a productive job to do. When tubulin is present at sufficient levels, it engages Tau and alpha-synuclein in constructive activity — building and stabilizing the microtubule network. When they are occupied in that healthy role, they do not have the conditions to misfold and aggregate into toxic clumps.
| Finding | Detail |
| Key protein identified | Tubulin (building block of neuronal microtubules) |
| Proteins prevented from aggregating | Tau (Alzheimer's) and alpha-synuclein (Parkinson's) |
| Mechanism | Tubulin redirects Tau and alpha-synuclein condensates from pathological to physiological states |
| Diseases targeted | Alzheimer's disease and Parkinson's disease |
| Prior understanding of tubulin's role | Passive casualty of neurodegeneration |
| New understanding | Active protector against toxic protein aggregation |
| Significance of low tubulin in AD brains | May be early driver of aggregation, not just a consequence |
| Published in | Nature Communications (June 21, 2026) |
A Reframe with Therapeutic Implications
Dr. Ferreon stated the significance directly: "Our findings significantly shift tubulin's role in neurodegeneration, from a passive casualty of disease to an active protector against toxic protein aggregation. Boosting the tubulin pool, rather than blocking droplet formation, can curb toxic aggregation while preserving the healthy roles of Tau and alpha-synuclein, offering a potential selective therapeutic strategy."
This reframing matters clinically. It is well-established that tubulin levels in the brain decline in Alzheimer's disease. The prevailing assumption has been that this decline is a consequence of neurodegeneration, neurons dying and losing their cytoskeletal infrastructure. The Baylor finding suggests a different possibility: that low tubulin levels may be a contributing cause of pathological protein aggregation, not just an effect. If tubulin depletion creates conditions in which Tau and alpha-synuclein are more likely to misfold, then restoring or maintaining tubulin levels might prevent aggregation from beginning.
As Neuroscience News summarized the findings, the dual-disease relevance of tubulin, regulating both Tau in Alzheimer's and alpha-synuclein in Parkinson's, means that a single tubulin-based therapeutic strategy could potentially address multiple neurodegenerative conditions simultaneously. Low tubulin levels could also serve as an early biomarker, a measurable signal of when the protective balance is shifting before irreversible aggregation begins.
The research group at Baylor will next examine how tubulin affects other protein condensates implicated in neurodegeneration and seek to better understand the mechanisms that shift condensates between pathological and physiological states. Drug development targeting tubulin levels is a future step; the current study establishes the mechanistic rationale that would justify that effort.
Frequently Asked Questions
What is tubulin, and what does it normally do in the brain?
Tubulin is the fundamental protein building block of microtubules — the internal transport network inside neurons. Microtubules function as the neuron's "railway tracks," moving nutrients, signals, and cellular waste throughout the cell. Tubulin is essential to neuron function and structure.
How does tubulin prevent Alzheimer's and Parkinson's protein aggregation?
The Baylor study found that tubulin engages Tau and alpha-synuclein in their healthy functional roles, building and stabilizing the microtubule network, which prevents them from entering the misfolded, aggregated states that drive Alzheimer's and Parkinson's pathology.
Why is the discovery that tubulin is an "active protector" significant?
Previously, the decline of tubulin in Alzheimer's and Parkinson's disease brains was assumed to be a consequence of neurodegeneration. The Baylor findings suggest tubulin depletion may instead be a contributing cause, creating conditions in which Tau and alpha-synuclein are more likely to form toxic aggregates. This shifts the therapeutic target from removing existing aggregates to preventing them from forming.
Is this a treatment for Alzheimer's or Parkinson's?
Not yet. The current study establishes the biological mechanism in cell and molecular models. Human clinical applications require further research to develop safe ways to boost or restore tubulin function in the brain. However, the findings provide a scientific rationale for pursuing tubulin-based preventive strategies.
Where was the study published?
The study was published in Nature Communications by Dr. Lathan Lucas, Dr. Phoebe S. Tsoi, and colleagues under the direction of Dr. Allan Chris M. Ferreon at Baylor College of Medicine. It was reported by ScienceDaily on June 21, 2026.
